Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Decreasing Hemorrhage Risk in Children With Alagille Syndrome
The goal of this interventional study is to test a hemostasis screening protocol and cardiac peri-procedural and post-operative hemostasis pathway to improving bleeding complications and improve patient survival for children with Alagille syndrome and complex cardiac conditions. The main questions it aims to answer are:
- Are children with Alagille syndrome with cardiac anomalies more likely to have acquired von Willebrand syndrome (a condition that causes increased bleeding)
- Does implementation of a novel screening protocol to detect pre-operative bleeding conditions decrease intra-operative and/or post-operative bleeding complications and mortality risk?
- Does implementation of a novel screening protocol to detect and treat bleeding conditions cause thrombotic complications?
Participants will undergo additional hematology and bleeding disorder screening prior to cardiac surgery. They will additionally undergo a detailed family screening for a history of bleeding by a genetic counselor.
Researchers will compare these findings with children who have similar complex cardiac conditions requiring surgery, but who do not have Alagille syndrome to see if bleeding conditions and complications are more or less common in children with Alagille syndrome.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Assessment for bleeding disorder with tailored post-operative care
Eligibility
Inclusion Criteria:
- 0-17 years old
- with complex cardiac condition requiring pulmonary artery reconstruction (branch
pulmonary artery stenosis, MAPCAs or Tetralogy of Fallot without MAPCAs)
Exclusion Criteria:
- history of known bleeding disorder
- aged 18 years or older
Ages Eligible for Study
N/A - 17 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Psoriasis Clinical Trials
Decreasing Hemorrhage Risk in Children With Alagille Syndrome
The goal of this interventional study is to test a hemostasis screening protocol and cardiac peri-procedural and post-operative hemostasis pathway to improving bleeding complications and improve patient survival for children with Alagille syndrome and complex cardiac conditions. The main questions it aims to answer are:
- Are children with Alagille syndrome with cardiac anomalies more likely to have acquired von Willebrand syndrome (a condition that causes increased bleeding)
- Does implementation of a novel screening protocol to detect pre-operative bleeding conditions decrease intra-operative and/or post-operative bleeding complications and mortality risk?
- Does implementation of a novel screening protocol to detect and treat bleeding conditions cause thrombotic complications?
Participants will undergo additional hematology and bleeding disorder screening prior to cardiac surgery. They will additionally undergo a detailed family screening for a history of bleeding by a genetic counselor.
Researchers will compare these findings with children who have similar complex cardiac conditions requiring surgery, but who do not have Alagille syndrome to see if bleeding conditions and complications are more or less common in children with Alagille syndrome.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Assessment for bleeding disorder with tailored post-operative care
Eligibility
Inclusion Criteria:
- 0-17 years old
- with complex cardiac condition requiring pulmonary artery reconstruction (branch
pulmonary artery stenosis, MAPCAs or Tetralogy of Fallot without MAPCAs)
Exclusion Criteria:
- history of known bleeding disorder
- aged 18 years or older
Ages Eligible for Study
N/A - 17 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Dermatology Clinical Trials
Decreasing Hemorrhage Risk in Children With Alagille Syndrome
The goal of this interventional study is to test a hemostasis screening protocol and cardiac peri-procedural and post-operative hemostasis pathway to improving bleeding complications and improve patient survival for children with Alagille syndrome and complex cardiac conditions. The main questions it aims to answer are:
- Are children with Alagille syndrome with cardiac anomalies more likely to have acquired von Willebrand syndrome (a condition that causes increased bleeding)
- Does implementation of a novel screening protocol to detect pre-operative bleeding conditions decrease intra-operative and/or post-operative bleeding complications and mortality risk?
- Does implementation of a novel screening protocol to detect and treat bleeding conditions cause thrombotic complications?
Participants will undergo additional hematology and bleeding disorder screening prior to cardiac surgery. They will additionally undergo a detailed family screening for a history of bleeding by a genetic counselor.
Researchers will compare these findings with children who have similar complex cardiac conditions requiring surgery, but who do not have Alagille syndrome to see if bleeding conditions and complications are more or less common in children with Alagille syndrome.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Assessment for bleeding disorder with tailored post-operative care
Eligibility
Inclusion Criteria:
- 0-17 years old
- with complex cardiac condition requiring pulmonary artery reconstruction (branch
pulmonary artery stenosis, MAPCAs or Tetralogy of Fallot without MAPCAs)
Exclusion Criteria:
- history of known bleeding disorder
- aged 18 years or older
Ages Eligible for Study
N/A - 17 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Pediatric Dermatology Clinical Trials
Decreasing Hemorrhage Risk in Children With Alagille Syndrome
The goal of this interventional study is to test a hemostasis screening protocol and cardiac peri-procedural and post-operative hemostasis pathway to improving bleeding complications and improve patient survival for children with Alagille syndrome and complex cardiac conditions. The main questions it aims to answer are:
- Are children with Alagille syndrome with cardiac anomalies more likely to have acquired von Willebrand syndrome (a condition that causes increased bleeding)
- Does implementation of a novel screening protocol to detect pre-operative bleeding conditions decrease intra-operative and/or post-operative bleeding complications and mortality risk?
- Does implementation of a novel screening protocol to detect and treat bleeding conditions cause thrombotic complications?
Participants will undergo additional hematology and bleeding disorder screening prior to cardiac surgery. They will additionally undergo a detailed family screening for a history of bleeding by a genetic counselor.
Researchers will compare these findings with children who have similar complex cardiac conditions requiring surgery, but who do not have Alagille syndrome to see if bleeding conditions and complications are more or less common in children with Alagille syndrome.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Assessment for bleeding disorder with tailored post-operative care
Eligibility
Inclusion Criteria:
- 0-17 years old
- with complex cardiac condition requiring pulmonary artery reconstruction (branch
pulmonary artery stenosis, MAPCAs or Tetralogy of Fallot without MAPCAs)
Exclusion Criteria:
- history of known bleeding disorder
- aged 18 years or older
Ages Eligible for Study
N/A - 17 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Decreasing Hemorrhage Risk in Children With Alagille Syndrome
The goal of this interventional study is to test a hemostasis screening protocol and cardiac peri-procedural and post-operative hemostasis pathway to improving bleeding complications and improve patient survival for children with Alagille syndrome and complex cardiac conditions. The main questions it aims to answer are:
- Are children with Alagille syndrome with cardiac anomalies more likely to have acquired von Willebrand syndrome (a condition that causes increased bleeding)
- Does implementation of a novel screening protocol to detect pre-operative bleeding conditions decrease intra-operative and/or post-operative bleeding complications and mortality risk?
- Does implementation of a novel screening protocol to detect and treat bleeding conditions cause thrombotic complications?
Participants will undergo additional hematology and bleeding disorder screening prior to cardiac surgery. They will additionally undergo a detailed family screening for a history of bleeding by a genetic counselor.
Researchers will compare these findings with children who have similar complex cardiac conditions requiring surgery, but who do not have Alagille syndrome to see if bleeding conditions and complications are more or less common in children with Alagille syndrome.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Assessment for bleeding disorder with tailored post-operative care
Eligibility
Inclusion Criteria:
- 0-17 years old
- with complex cardiac condition requiring pulmonary artery reconstruction (branch
pulmonary artery stenosis, MAPCAs or Tetralogy of Fallot without MAPCAs)
Exclusion Criteria:
- history of known bleeding disorder
- aged 18 years or older
Ages Eligible for Study
N/A - 17 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Decreasing Hemorrhage Risk in Children With Alagille Syndrome
The goal of this interventional study is to test a hemostasis screening protocol and cardiac peri-procedural and post-operative hemostasis pathway to improving bleeding complications and improve patient survival for children with Alagille syndrome and complex cardiac conditions. The main questions it aims to answer are:
- Are children with Alagille syndrome with cardiac anomalies more likely to have acquired von Willebrand syndrome (a condition that causes increased bleeding)
- Does implementation of a novel screening protocol to detect pre-operative bleeding conditions decrease intra-operative and/or post-operative bleeding complications and mortality risk?
- Does implementation of a novel screening protocol to detect and treat bleeding conditions cause thrombotic complications?
Participants will undergo additional hematology and bleeding disorder screening prior to cardiac surgery. They will additionally undergo a detailed family screening for a history of bleeding by a genetic counselor.
Researchers will compare these findings with children who have similar complex cardiac conditions requiring surgery, but who do not have Alagille syndrome to see if bleeding conditions and complications are more or less common in children with Alagille syndrome.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Assessment for bleeding disorder with tailored post-operative care
Eligibility
Inclusion Criteria:
- 0-17 years old
- with complex cardiac condition requiring pulmonary artery reconstruction (branch
pulmonary artery stenosis, MAPCAs or Tetralogy of Fallot without MAPCAs)
Exclusion Criteria:
- history of known bleeding disorder
- aged 18 years or older
Ages Eligible for Study
N/A - 17 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting